Oat cell carcinoma of the lung:A review of 138 cases

Abstract

All cases seen during the 11 years from 1956 through 1966 are reviewed. They comprised 10% of the bronchogenic cancer population. Males predominated 19:1. There was no positive correlation with cigarette smoking. In most of the patients symptoms were present less than 3 months before diagnosis. Only four patients (3.0%) had overt hypercoticism. Histologic confirmation was easily obtained; bronchoscopic biopsy was positive in 60% of the cases. Our operability rate (60%) and resectability rate (27%) are almost as high as for epidermoid carcinoma; others have reported much lower rates. There are two 5‐year survivors, the only asymptomatic patients in the series. In both, the tumor already had prominent vascular invasion, and one had regional lymph node involvement. The survival rate was 5.4% of the resected patients and 1.4% of the total group.

Immune Checkpoint Inhibitors in Extensive Disease Small Cell Lung Cancer

“…Prognosis in SCLC is poor. Median survival without treatment has been reported as 2-4 months [4]. Until now treatment of SCLC remains a tremendous challenge for oncologists.…”

Treatment of limited disease small cell lung cancer: the multidisciplinary team

“…Core team members communicate closely and involve a multitude of other agents, e.g. general practitioners, social workers, physiotherapists, administrators, clinical trial specialists and nurses, to achieve the best possible results for the patient [1,5,6].…”

“…A systematic review by COORY et al [3] identified only one randomised trial [13] including SCLC investigating the impact of MDTs. Despite lacking evidence for SCLC, evidence from breast, head-and-neck and rectal cancer has demonstrated that MDTs can reduce rates of positive surgical margins, reduce costs, improve patient satisfaction, improve documentation regarding TNM (tumour, nodes, metastasis) staging or performance status and even decrease the time from diagnosis to treatment [5,[14][15][16][17].…”

“…Without treatment, patients with SCLC rarely survive longer than a few weeks to months [5]. Insufficient or late treatments have been associated with poor outcomes [18][19][20].…”

Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience

“…1 SCLC is characterized by a rapid doubling time, high growth fraction, paraneoplastic endocrinopathies, and early development of widespread metastases: at diagnosis, approximately two-thirds of patients have extensive-stage disease (ED). 1,2 Combination chemotherapy guarantees a high objective response rate but progression-free survival (PFS) is disappointing and long-term overall survival (OS) remains usually < 12 months. 3,4 Cisplatin (P) and etoposide (E) is the most used chemotherapy regimen in SCLC.…”